Fig 7.

Intracerebroventricularly injected U18666A impairs the IGF-1-Akt signaling and induces an accumulation of amyloid β in the temporal lobes. (a). Western blotting demonstrating changes in the levels of expression or phosphorylated status of the indicated proteins. Rats were intracerebroventricularly injected with U18666A or PBS at 0, 7, 14, or 21 days and then sacrificed. The total proteins were extracted from the tissues of the temporal lobes (30 μg/lane) and then subjected to western blotting with anti-phospho-Akt (p-Ser473), anti-Akt, anti-phospho-GSK-3β (p-Ser-9), anti-GSK-3β, anti-phospho-Tau (p-Ser404), anti-Tau, anti-Aβ, anti-NSE, and anti-actin antibodies. (b). A plot showing the intensities of the bands in the blot depicted in panel a. The levels of phosphorylated proteins were normalized against the level of each total proteins, and then expressed as a percent of the highest level of the phosphorylated form for each group. Data are indicated as the mean ± SDs from 8 rats. '*' indicates significantly different from the level at day 0 at p < 0.05.